Shionogi-ViiV Healthcare, a JV involving GSK, Pfizer (PFE) and Shionogi, says a Phase III trial...

|By:, SA News Editor

Shionogi-ViiV Healthcare, a JV involving GSK, Pfizer (PFE) and Shionogi, says a Phase III trial of its dolutegravir HIV treatment suggests it might be more effective than Gilead's (GILD) and Bristol-Myers Squibb's (BMY) Atripla drug. GSK shares +0.3% in London. (PR)